Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Authors
Keywords
Mucosal changes, Oral cavity, Mucositis, Stomatitis, Mucosal sensitivity, Dysgeusia, Xerostomia, Lichenoid reaction, Hyperkeratotic lesion, Oral squamous cell carcinoma, Benign migratory glossitis, Hyperpigmentation, Angiogenesis inhibitors, EGFR inhibitors, BRAF inhibitors, mTOR inhibitors, BCR-ABL inhibitor, Cancer, Targeted therapies, Immune checkpoint inhibitors, Immunotherapy, Oral adverse events, Osteonecrosis of jaw, mIAS, Telangiectasias, Anti-PD-1
Journal
SUPPORTIVE CARE IN CANCER
Volume 25, Issue 5, Pages 1713-1739
Publisher
Springer Nature
Online
2017-02-22
DOI
10.1007/s00520-017-3629-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
- (2016) H. S. Rugo et al. ANNALS OF ONCOLOGY
- Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma
- (2016) Guopei Zhu et al. BMC CANCER
- Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer
- (2016) Hope S. Rugo Clinical Breast Cancer
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
- (2016) Vincent Sibaud et al. CURRENT OPINION IN ONCOLOGY
- Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial
- (2016) James A. Bonner et al. EUROPEAN JOURNAL OF CANCER
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
- (2016) Lars Hofmann et al. EUROPEAN JOURNAL OF CANCER
- Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology
- (2016) Vittorio Fusco et al. Expert Opinion On Drug Safety
- Emerging targeted therapies for melanoma
- (2016) Douglas B. Johnson et al. EXPERT OPINION ON EMERGING DRUGS
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial
- (2016) Stefano Maria Magrini et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
- (2016) Kurt B. Schaberg et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
- (2016) Nadia Harbeck et al. LANCET ONCOLOGY
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
- (2016) Andrew J Armstrong et al. LANCET ONCOLOGY
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Understanding the impact of taste changes in oncology care
- (2016) Joel B. Epstein et al. SUPPORTIVE CARE IN CANCER
- Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols
- (2016) Judith A. E. M. Zecha et al. SUPPORTIVE CARE IN CANCER
- Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
- (2016) Veronica J. Shi et al. JAMA Dermatology
- Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice
- (2016) Douglas E. Peterson et al. Cancer Medicine
- Oral and Cutaneous Lichenoid Eruption with Nail Changes Due to Imatinib Treatment in a Chinese Patient with Chronic Myeloid Leukemia
- (2015) Jiang An Zhang et al. Annals of Dermatology
- Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up
- (2015) D. E. Peterson et al. ANNALS OF ONCOLOGY
- Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors
- (2015) E. Vigarios et al. BRITISH JOURNAL OF DERMATOLOGY
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
- (2015) Francesco Leone et al. CANCER
- Incidence and Risk of High-grade Stomatitis with mTOR Inhibitors in Cancer Patients
- (2015) Raji Shameem et al. CANCER INVESTIGATION
- Drug induced osteonecrosis of the jaw
- (2015) Issam S. Hamadeh et al. CANCER TREATMENT REVIEWS
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials
- (2015) Marco Miroddi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immune Therapy in GI Malignancies: A Review
- (2015) Judy Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- (2015) Assuntina G. Sacco et al. JOURNAL OF CLINICAL ONCOLOGY
- Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis
- (2015) Elise Gaudin et al. JOURNAL OF CLINICAL PERIODONTOLOGY
- Cutaneous adverse effects of targeted therapies
- (2015) James B. Macdonald et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cutaneous adverse effects of targeted therapies
- (2015) James B. Macdonald et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Vemurafenib mucosal side-effect
- (2015) A. Pileri et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
- (2015) Christophe Tournigand et al. LANCET ONCOLOGY
- Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
- (2015) Nicole Basset-Seguin et al. LANCET ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
- (2015) M. Burotto et al. ONCOLOGIST
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
- (2015) G. K. Pennock et al. ONCOLOGIST
- Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors
- (2015) Anna Yuan et al. ORAL ONCOLOGY
- Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw
- (2015) Reginald H. Goodday Oral and Maxillofacial Surgery Clinics of North America
- Adverse drug events in the oral cavity
- (2015) Anna Yuan et al. Oral Surgery Oral Medicine Oral Pathology Oral Radiology
- Toxicité endobuccale des thérapies ciblées anticancéreuses
- (2014) V. Sibaud et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- T-DM1-related telangiectasias: a potential role in secondary bleeding events
- (2014) V. Sibaud et al. ANNALS OF ONCOLOGY
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
- (2014) H. S. Rugo et al. ANNALS OF ONCOLOGY
- Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series
- (2014) Vincent Sibaud et al. BREAST CANCER RESEARCH AND TREATMENT
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
- (2014) Rajesh V. Lalla et al. CANCER
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
- (2014) Aliya A Khan et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
- (2014) K. Kian Ang et al. JOURNAL OF CLINICAL ONCOLOGY
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
- (2014) Salvatore L. Ruggiero et al. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma
- (2014) Aaron R. Mangold et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- (2014) Claire Marie Reyes-Habito et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The malignant transformation of oral lichen planus and oral lichenoid lesions
- (2014) Sarah G. Fitzpatrick et al. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
- (2014) Peter M Ellis et al. LANCET ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
- (2014) Pasi A Jänne et al. LANCET ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
- (2014) Suresh S Ramalingam et al. LANCET ONCOLOGY
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
- (2014) John Primrose et al. LANCET ONCOLOGY
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in Metastatic Thyroid Cancer: A Systematic Review
- (2014) L. Thomas et al. ONCOLOGIST
- Oral health in oncology: impact of immunotherapy
- (2014) Leanne K. Jackson et al. SUPPORTIVE CARE IN CANCER
- Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT)
- (2014) Sharon Elad et al. SUPPORTIVE CARE IN CANCER
- Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials
- (2014) Zhong-chuan Lv et al. TUMOR BIOLOGY
- Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
- (2013) L. Boussemart et al. ANNALS OF ONCOLOGY
- Everolimus: side effect profile and management of toxicities in breast cancer
- (2013) Elisavet Paplomata et al. BREAST CANCER RESEARCH AND TREATMENT
- Osteonecrosis of the jaw related to everolimus: a case report
- (2013) Dong Wook Kim et al. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral mucosal injury caused by cancer therapies: current management and new frontiers in research
- (2013) Siri B. Jensen et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib
- (2013) Anne Lynn S. Chang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial
- (2013) Edward S Kim et al. LANCET ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Geographic Tongue Induced by Angiogenesis Inhibitors
- (2013) T. Hubiche et al. ONCOLOGIST
- In Reply
- (2013) A. C. Rosen et al. ONCOLOGIST
- Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma
- (2013) K. R. Sampat et al. ONCOLOGIST
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
- (2013) M. E. Lacouture et al. ONCOLOGIST
- A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
- (2013) Fabiana Martins et al. ORAL ONCOLOGY
- Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
- (2013) Mary E. Peterson SUPPORTIVE CARE IN CANCER
- Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis
- (2013) Linda S. Elting et al. SUPPORTIVE CARE IN CANCER
- Systematic review of basic oral care for the management of oral mucositis in cancer patients
- (2013) Deborah B. McGuire et al. SUPPORTIVE CARE IN CANCER
- Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer
- (2013) Hiroo Imai et al. BMC Palliative Care
- Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
- (2012) Ezzeldin M. Ibrahim et al. International Journal of Clinical Oncology
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
- (2012) Emily Y. Chu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- (2012) Vincent A Miller et al. LANCET ONCOLOGY
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
- (2012) Paul E Goss et al. LANCET ONCOLOGY
- Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT
- (2012) Teh-Liane Khoo et al. LEUKEMIA & LYMPHOMA
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment
- (2012) I. T. Gavrilovic et al. ONCOLOGIST
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- (2012) Caroline Robert et al. SEMINARS IN ONCOLOGY
- Targeted therapy in head and neck cancer
- (2012) S. K. Kundu et al. TUMOR BIOLOGY
- Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
- (2011) Camillo Porta et al. BMC CANCER
- Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
- (2011) IRIS AMITAY-LAISH et al. Dermatologic Therapy
- Drug-Induced Taste and Smell Alterations
- (2011) Marco Tuccori et al. DRUG SAFETY
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
- (2011) Camillo Porta et al. EUROPEAN JOURNAL OF CANCER
- The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
- (2011) Cristina Gomez-Fernandez et al. EUROPEAN JOURNAL OF CANCER
- EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis
- (2011) Peng Chen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group
- (2011) Kim Edmonds et al. European Journal of Oncology Nursing
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
- (2011) Stephen M Ansell et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review
- (2011) C. B. Boers-Doets et al. ONCOLOGIST
- Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities
- (2011) C. Kollmannsberger et al. ONCOLOGIST
- Oral complications in the treatment of cancer patients
- (2011) DD Mosel et al. ORAL DISEASES
- Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma
- (2011) D.I. Pryor et al. ORAL ONCOLOGY
- Clinical presentation and management of mTOR inhibitor-associated stomatitis
- (2011) Marcio Augusto de Oliveira et al. ORAL ONCOLOGY
- Oral complications of targeted cancer therapies: A narrative literature review
- (2011) A.L. Watters et al. ORAL ONCOLOGY
- Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases
- (2011) U. Mattsson et al. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS
- Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas
- (2011) Noriko Nishimura et al. SUPPORTIVE CARE IN CANCER
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
- (2011) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- mTOR inhibitor-associated dermatologic and mucosal problems
- (2010) Josep M. Campistol et al. CLINICAL TRANSPLANTATION
- Taste Alterations in Cancer Patients Receiving Chemotherapy: A Neglected Side Effect?
- (2010) A. Zabernigg et al. ONCOLOGIST
- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group
- (2010) Mario E. Lacouture et al. SUPPORTIVE CARE IN CANCER
- Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy
- (2009) Ajay Tejwani et al. CANCER
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- (2009) James A Bonner et al. LANCET ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone
- (2009) C. Christodoulou et al. ONCOLOGY
- Mucositis: The impact, biology and therapeutic opportunities of oral mucositis
- (2009) Stephen T. Sonis ORAL ONCOLOGY
- Taste disorders in cancer patients: Pathogenesis, and approach to assessment and management
- (2009) Joel B. Epstein et al. ORAL ONCOLOGY
- Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
- (2008) Eric Raymond et al. JOURNAL OF CLINICAL ONCOLOGY
- Dermatologic symptoms associated with the multikinase inhibitor sorafenib
- (2008) Caroline Robert et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Skin and oral lesions associated to imatinib mesylate therapy
- (2008) Fernanda Gonçalves Basso et al. SUPPORTIVE CARE IN CANCER
- Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
- (2008) S. E. Rosenbaum et al. SUPPORTIVE CARE IN CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now